Kidney & blood pressure research最新文献

{"title":"Expert Opinion on the Conceptual, Clinical, and Therapeutic Aspects of Fabry Nephropathy: A Nephrologists' Perspective.","authors":"Necmi Eren, Kultigin Turkmen, Faruk Turgut, Bulent Tokgoz, Ayca Inci, Nurhan Seyahi","doi":"10.1159/000552715","DOIUrl":"10.1159/000552715","url":null,"abstract":"<p><strong>Background: </strong>Progressive nephropathy (Fabry nephropathy), as observed in both the early-onset and later-onset types of Fabry disease and in as many as 50% of males and 20% of females, represents a major driver of overall disease burden in this population. Nonetheless, recognizing and diagnosing Fabry nephropathy remains clinically demanding for nephrologists given its pivotal role in altering disease progression and improving patients' quality of life. Therapeutics presents additional complexity as evidence-based criteria for treatment and prognostic algorithms remain limited.</p><p><strong>Summary: </strong>Against this background, this expert opinion aims to address the current knowledge on conceptual, clinical, and therapeutic aspects of Fabry nephropathy from a nephrologist's perspective and to provide a guidance document for the best practice in the management and monitoring of the disease.</p><p><strong>Key messages: </strong>The participating experts considered the indispensable role of heightened disease awareness among nephrologists, the maintenance of a high diagnostic index in symptomatic individuals, and the importance of systematic screening of at-risk populations to enable prompt identification of Fabry nephropathy. This is particularly important in the current availability of enzymatic and genetic screening tests and the specific disease-modifying treatments capable of decelerating kidney function deterioration when initiated at an early disease stage. Implementation of a multidisciplinary approach with an experienced team of clinicians, and continued monitoring and assessment of clinical status are considered critical to optimal patient care, as well as the timely initiation of ERT in conjunction with appropriately selected adjunctive treatments within a care plan individualized to the patient's clinical signs and symptoms.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"836-859"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease.","authors":"Carissa L Birznieks, Wei Wang, Cortney Steele, Zhiying You, Berenice Gitomer, Michel Chonchol, Kristen L Nowak","doi":"10.1159/000550949","DOIUrl":"10.1159/000550949","url":null,"abstract":"<p><strong>Introduction: </strong>We have previously reported that overweight and obesity are independently associated with more rapid disease progression in adults with autosomal dominant polycystic kidney disease (ADPKD). In this study, we perform a cross-sectional analysis to evaluate whether overweight and obesity are also associated with renal blood flow (RBF) in this patient population.</p><p><strong>Methods: </strong>A total of 134 non-diabetic adults with ADPKD and estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 who participated in a randomized controlled trial of pravastatin therapy were categorized as normal weight, overweight, or obese, based on baseline adjusted body mass index (BMI), calculated after subtracting magnetic resonance imaging (MRI)-derived kidney and liver mass from body weight. RBF was measured by phase contrast MRI and adjusted for body surface area (BSA) prior to analysis. The association of baseline BMI with baseline RBF was assessed using multivariable linear regression models.</p><p><strong>Results: </strong>Participants were 40 ± 10 years (mean ± SD), 67% female, with a baseline RBF of 635 ± 214 mL/min/1.73 m2, and a baseline Chronic Kidney Disease Epidemiology (CKD-EPID) eGFR of 90 ± 21 mL/min/1.73 m2. BSA-adjusted RBF was lower in a stepwise manner with increasing BMI category. After adjustment for demographics, systolic blood pressure, blood glucose, high-density lipoprotein, blood pressure medication usage, eGFR, and height-adjusted total kidney volume, both overweight (β-estimate: -78.4; 95% CI: -155.3, -1.6) and obesity (β-estimate: -190.6; 95% CI: -307.4, -73.7) remained significantly associated with lower RBF as compared to normal weight participants. For every one unit increase in BMI, RBF was 10.4 mL/min/1.73 m2 lower (95% CI: -16.9, -3.9) in the fully adjusted model.</p><p><strong>Conclusion: </strong>Overweight and obesity are cross-sectionally associated with lower RBF in patients with early-stage ADPKD; however, these findings reflect associations only and do not provide insight into causality. Further research and longitudinal studies are needed to establish the temporal and causal nature of these relationships and to evaluate whether reduced RBF may be a mechanism by which obesity is associated with faster progression in patients with ADPKD.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"218-224"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13103952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing the Efficacy of Low-Dose Spironolactone in Adults with Chronic Kidney Disease and Type 2 Diabetes: A post hoc Analysis.","authors":"Shohei Takayama, Ako Oiwa, Masayoshi Koinuma, Teiji Takeda, Takahide Miyamoto, Dai Hiwatashi, Mitsuhisa Komatsu","doi":"10.1159/000549942","DOIUrl":"10.1159/000549942","url":null,"abstract":"<p><strong>Introduction: </strong>We previously reported the efficacy and safety of low-dose (12.5 mg/day) spironolactone for chronic kidney disease (CKD) with diabetes. Few studies have examined the characteristics of patients who may have reduced urinary albumin-creatinine ratio (UACR) on mineralocorticoid receptor antagonists. In this study, we aimed to identify the clinical characteristics of patients prone to benefit from UACR reduction with low-dose spironolactone.</p><p><strong>Methods: </strong>This was a post hoc analysis of a previous trial and included 55 patients assigned to the spironolactone group. Univariate regression analysis was performed to determine the association between the change in UACR after 24 weeks of low-dose spironolactone administration and baseline exploratory parameters. Multiple regression analysis was conducted on the associated parameters, and regression models were created for analysis. A similar analysis was performed for changes in serum potassium levels and estimated glomerular filtration rate (eGFR) after 24 weeks of spironolactone administration.</p><p><strong>Results: </strong>In the univariate analysis, baseline UACR, triglyceride levels, and eGFR were associated with changes in UACR. The regression coefficient estimates were significant for baseline UACR, triglyceride levels, and eGFR (p = 0.002, 0.017, and 0.003, respectively). The reduction in UACR was greater with higher baseline UACR and triglyceride levels, and lower baseline eGFRs. The increase in serum potassium levels due to low-dose spironolactone administration showed a negative correlation with baseline serum potassium levels and no correlation with baseline eGFR, suggesting its safety.</p><p><strong>Conclusions: </strong>It may not be too late to start treatment with low-dose spironolactone, even in patients with relatively advanced CKD with diabetes.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"50-60"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infective Endocarditis-Associated Glomerulonephritis Caused by <i>Streptococcus cristatus</i>: A Case Report.","authors":"Yuta Nakagawa, Chie Yamamoto, Mari Morimoto, Satoshi Numata, Yoko Nukui","doi":"10.1159/000553296","DOIUrl":"10.1159/000553296","url":null,"abstract":"<p><strong>Introduction: </strong>Infective endocarditis (IE) can trigger systemic embolic and immune-mediated complications, including infection-related glomerulonephritis. When the infectious focus is IE, the condition is termed IE-associated glomerulonephritis (IEAGN). A major diagnostic pitfall is that IEAGN may present with purpura, nephritic urinary abnormalities, systemic inflammation, and antineutrophil cytoplasmic antibody (ANCA) positivity, closely mimicking primary small-vessel vasculitis and risking inappropriate immunosuppression if infection is not promptly excluded.</p><p><strong>Case presentation: </strong>A 52-year-old woman with mitral valve prolapse presented with fever, malaise, and palpable purpura. Laboratory testing demonstrated systemic inflammation, renal dysfunction with proteinuria and hematuria, and marked proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) positivity (121 U/mL). Blood cultures obtained for persistent fever yielded Streptococcus cristatus. Transesophageal echocardiography demonstrated large vegetations on the mitral valve (19 mm on the anterior leaflet and 11 mm on the posterior leaflet), with severe mitral regurgitation. Neuroimaging identified a right occipital hemorrhage and small peripheral intracranial aneurysms. Kidney biopsy demonstrated necrotizing and crescentic glomerulonephritis with a granular immune-complex staining pattern on immunofluorescence (C3/C1q/IgG/IgM/IgA) and mesangial electron-dense deposits on electron microscopy, supporting an immune-complex-mediated glomerulonephritis in the setting of IE. She was treated with ceftriaxone and underwent early mitral valve replacement for large vegetations, severe mitral regurgitation, and disseminated lesions. Renal function improved without corticosteroids or other immunosuppressants. During more than 8 weeks of antibiotic therapy, her serum PR3-ANCA level decreased from 121 to 63.8 U/mL by hospital day 73.</p><p><strong>Conclusion: </strong>S. cristatus IE can present with vasculitis-like features and a markedly elevated serum PR3-ANCA concentration, closely mimicking ANCA-associated vasculitis. This case emphasizes that ANCA positivity does not rule out infection and highlights the importance of early integration of blood cultures, echocardiography, and renal pathology to support clinicopathological diagnosis and avoid premature immunosuppression.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"658-668"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13450983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.","authors":"Rulong Chen, Jinxin Zhang, Jiating Chen, Tingfei Xie, Yunpeng Xu, Zhaoyong Hu, Jihong Chen","doi":"10.1159/000552201","DOIUrl":"10.1159/000552201","url":null,"abstract":"<p><strong>Introduction: </strong>Nondiabetic kidney disease (NDKD) is a major contributor to chronic kidney disease worldwide. Although renin-angiotensin system inhibitors (RASi) remain standard therapy, sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (non-steroidal MRAs), and glucagon-like peptide-1 receptor agonists are now recommended in clinical guidelines. However, direct comparative evidence to guide their prioritization in NDKD is limited.</p><p><strong>Methods: </strong>We performed a systematic review and Bayesian network meta-analysis of randomized controlled trials enrolling adults with NDKD. The primary endpoint was the annualized change in estimated glomerular filtration rate (eGFR) slope; secondary endpoints included urine protein-to-creatinine ratio (UPCR), blood pressure, and biochemical safety parameters.</p><p><strong>Results: </strong>Eighteen trials were included. SGLT2i, as add-on to RASi, produced the greatest preservation of kidney function compared with RASi alone (mean difference [MD] 12.1 mL/min/1.73 m2/year; 95% credible interval [CrI] 3.9 to 20.4). Non-steroidal MRA achieved the largest reduction in proteinuria versus RASi (UPCR MD -0.4 g/g; 95% CrI: -1.0 to -0.2). SGLT2i also yielded the greatest systolic blood pressure reduction versus RASi (MD -9.1 mm Hg vs. RASi; 95% CrI: -11.7 to -6.5). Surface-under-the-cumulative-ranking probabilities identified SGLT2i as most effective for eGFR slope preservation (99.8%) and non-steroidal MRA as most effective for proteinuria reduction (98.8%). Safety analyses showed a mild, expected hemoglobin decrease with SGLT2i and a nonsignificant creatinine rise with non-steroidal MRA.</p><p><strong>Conclusions: </strong>SGLT2i and non-steroidal MRA confer distinct renal benefits in NDKD - SGLT2i primarily preserve kidney function, whereas non-steroidal MRAs most effectively reduce proteinuria. These results support a phenotype-driven therapeutic framework and highlight the need for head-to-head trials to validate precision-guided treatment strategies in NDKD.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"409-420"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antithrombin in Hyperuricemic Nephropathy: Unveiling Its Noncanonical Renoprotective Roles and Therapeutic Repurposing Potential.","authors":"Lei Jin, Xiaomin Zhang, Feng Wang","doi":"10.1159/kbr/adjag005","DOIUrl":"10.1159/kbr/adjag005","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of hyperuricemic nephropathy (HN) is increasingly linked to a self-perpetuating cycle of thromboinflammation. This process begins with hyperuricemia-induced endothelial dysfunction, which activates both the coagulation cascade and inflammatory pathways, notably the pyrin domain-containing protein 3 inflammasome. This creates a vicious cycle of which inflammation promotes coagulation and coagulation products further amplify inflammation, ultimately leading to renal microvascular thrombosis, ischemia, and progressive fibrosis.</p><p><strong>Summary: </strong>This review critically examines the therapeutic potential of antithrombin (AT) in interrupting this pathogenic axis. AT, a key serine protease inhibitor, is central to physiological anticoagulation. Beyond its canonical role in neutralizing thrombin and factor Xa (FXa), AT exerts potent anti-inflammatory and endothelial-stabilizing effects, primarily mediated through interactions involving its D-helix domain. Compelling preclinical evidence from models of sepsis, ischemia-reperfusion, and diabetic nephropathy demonstrates that AT can attenuate inflammation, improve microcirculation, and reduce fibrosis. We hypothesize that in HN, augmenting AT levels may simultaneously dampen thrombin generation, quell the associated inflammatory response, and protect the endothelium, thereby potentially mitigating the structural drivers of renal decline. These findings suggest that AT might serve as a multi-target candidate for disease modification, pending validation in HN-specific models. Notably, this hypothesis remains untested in HN-specific models, with current evidence extrapolated from related thromboinflammatory conditions. Therefore, this review synthesizes the mechanistic rationale, clearly delineates established science from translational hypothesis, and identifies the crucial experimental gaps - particularly regarding optimal dosing, timing, and direct validation of efficacy in HN - that must be addressed to evaluate the potential of AT repurposing as a candidate targeted therapy for hyperuricemic kidney injury.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"887-902"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of renal artery stenosis on renovascular hypertension and the therapeutic role of renal artery stenting: a comprehensive review.","authors":"Changgang Shao, Guoqing Chi, Fang Li, Hongcheng Ren, Liyan Zhang, Jinming Yang, Bin Wang, Mingchao Ding","doi":"10.1159/000545135","DOIUrl":"10.1159/000545135","url":null,"abstract":"<p><p>Background Renal artery stenosis (RAS) is characterized by reduced renal perfusion, activating the renin-angiotensin-aldosterone system (RAAS), which can lead to secondary hypertension, ischemic nephropathy, and cardiac destabilization syndrome. These conditions have significant healthcare implications. Renovascular hypertension (RVH) in RAS patients can be managed through medical therapy and revascularization, either endovascular or surgical. While renal artery stenting (RAS) was once viewed as the most effective treatment for atherosclerotic renovascular disease, recent trials suggest no significant difference in RVH management between medical therapy alone and combined with renal artery stenting. However, certain subgroups have exhibited favorable outcomes in blood pressure control post-stenting. Summary This comprehensive review synthesizes data, including findings from the HERCULES trial, which showed a reduction in blood pressure from 162.3±18.5/77.7±11.5 mmHg to 145.7±20.7/75.4±11.0 mmHg over 36 months (P<0.0001). Additionally, the ASPIRE-2 study demonstrated significant decreases in blood pressures from 168±25/82±13 mmHg to 149±25/77±12 mmHg at 24 months (P<0.001). The review delves into the prevalence, pathophysiology, clinical manifestations, diagnosis, and treatment of RAS-related RVH, specifically analyzing the efficacy and safety of renal artery stenting. Key Messages The analysis indicates that renal artery stenting may be particularly advantageous for certain patient subgroups, enhancing blood pressure outcomes and overall clinical status. Nevertheless, the criteria for selecting candidates for this intervention remain under debate. Future research should focus on high-risk RAS patients to explore long-term benefits and refine the utilization of renal artery stents, ultimately improving RVH management.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Interplay of Factors in Chronic Kidney Disease: Insights from The Malaysian Cohort Study.","authors":"Noraidatulakma Abdullah, Norfazilah Ahmad, Azmawati Mohammed Nawi, Mohd Rohaizat Hassan, Ying-Xian Goh, Norliza Ismail, Nazihah Abd Jalal, Raihannah Othman, Azwa Shawani Kamalul Arifin, Mohd Arman Kamaruddin, Rahman Jamal","doi":"10.1159/000542732","DOIUrl":"10.1159/000542732","url":null,"abstract":"<p><strong>Introduction: </strong>There is an increasing prevalence of chronic kidney disease (CKD) in Malaysia; hence, identifying factors associated with the early stage of CKD is crucial for preventive measures. This study investigated the association between various factors and their interaction in a multi-ethnic Malaysian cohort.</p><p><strong>Methods: </strong>A nested case-control analysis was conducted on 3,160 eligible participants with renal profile data from The Malaysian Cohort project. CKD status was determined by estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation. Multiple logistic regression analysis using the likelihood ratio method was used to identify the factors and their interaction with CKD.</p><p><strong>Results: </strong>This study suggested five factors associated with CKD: gender, ethnicity, physical activity, atherogenic plasma index (AIP), and systolic blood pressure. There was an interaction between AIP and gender, with increased odds of CKD among men with high AIP.</p><p><strong>Conclusions: </strong>As CKD is mainly asymptomatic until it is in the later stages, these five factors serve as valuable tools for predicting CKD and enhancing the identification of at-risk individuals, particularly among men with elevated AIP. Future studies should focus on using these factors, especially in preventing new CKD cases and their progression.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"210-220"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating the Whole Urine and Urine Supernatant Protein Profiles of Preterm Infants via Urine Proteomics.","authors":"Lulu Zhang, Xueyan Wang, Dan Wu, Jun Zheng, Fangrui Ding","doi":"10.1159/000543714","DOIUrl":"10.1159/000543714","url":null,"abstract":"<p><strong>Introduction: </strong>Urine proteomics plays an important role in the screening of biomarkers for infant diseases. However, there is no unified standard for the selection of urine samples for urine proteomics. It is also unclear whether there are differences in proteomics between whole urine and urine supernatant. Therefore, the urine of preterm infants was used as the research sample to explore the differences in protein profiles between the whole urine and urine supernatant of preterm infants by proteomics.</p><p><strong>Methods: </strong>Urine samples were collected from five preterm infants with a gestational age of <28 weeks at their corrected gestational age of 37 weeks. Each preterm urine was divided into whole urine and supernatant. Urine protein was extracted and analyzed by liquid chromatography-tandem mass spectrometry.</p><p><strong>Results: </strong>The two groups of urine samples did not show significant clustering in the principal component analysis. A total of 2,607 proteins were detected in the two groups of urine samples, of which 82 proteins were unique to whole urine samples and 56 proteins were unique to urine supernatant samples. The molecular functions, the main biological processes, and subcellular localization of the differential proteins were analyzed. In other neonatal-related diseases, there was no significant difference in protein enrichment between whole urine and urine supernatant.</p><p><strong>Conclusions: </strong>This study analyzed the differences between whole urine and urine supernatant in urine proteomics of preterm infants. In neonatal-related diseases, there is no significant difference in urinary protein biomarkers between whole urine and urine supernatant.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"198-209"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease.","authors":"Daniel Patschan, Igor Matyukhin, Friedrich Stasche, Oliver Ritter, Susann Patschan","doi":"10.1159/000544810","DOIUrl":"10.1159/000544810","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory rheumatic diseases regularly require the use of disease-modifying antirheumatic drugs (DMARDs). The use of DMARDs in patients with end-stage chronic kidney disease (CKD stage 5D) is particularly challenging due to the lack of systematic studies available for this patient population. This narrative review aimed to address the aspect of DMARD therapy in CKD 5D.</p><p><strong>Summary: </strong>The current article is a narrative review. References were sourced from the following databases: PubMed, Web of Science, Cochrane Library, and Scopus. The search period spanned from 1975 to 2024. There is a notable lack of systematic data on this topic. The available literature was reviewed to provide insights, despite the limited availability of comprehensive studies. Individuals with terminal kidney disease can presumably be safely treated with leflunomide, mycophenolic acid, sulfasalazine, azathioprine, belimumab, and anti-CD20. For all other substances, there are either significant restrictions, insufficient data, or inadequate experience.</p><p><strong>Key messages: </strong>Some conventional and biologic DMARDs are available for the management of inflammatory rheumatic diseases in CKD stage 5D. It is essential to consider the limitations on kidney function, as they can significantly affect the pharmacokinetics of medications. Consequently, slightly more frequent checkups are recommended when using the defined preparations.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"249-258"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}